CAMBRIDGE, Mass., July 31, 2018 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a clinical-stage gene therapy company focused on developing treatments for severe neurological diseases, today announced its second quarter 2018 financial results and corporate highlights conference call and live webcast scheduled for Tuesday, August 7, 2018 at 4:30 p.m. EDT.
The live call may be accessed by dialing (877) 851-3834 for domestic callers, or +1 (631) 291-4595 for international callers, and referencing conference ID number 8498509. A live audio webcast of the conference call will be available online from the Investors & Media section of Voyager’s website at www.voyagertherapeutics.com. The webcast will be archived for 30 days.
About Voyager Therapeutics
Voyager Therapeutics is a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases. Voyager is committed to advancing the field of AAV gene therapy through innovation and investment in vector engineering and optimization, manufacturing and dosing and delivery techniques. Voyager’s pipeline focuses on severe neurological diseases in need of effective new therapies, including Parkinson’s disease, a monogenic form of ALS called SOD1, Huntington’s disease, Friedreich’s ataxia, neurodegenerative diseases related to defective or excess aggregation of tau protein in the brain including Alzheimer’s disease and severe, chronic pain. Voyager has broad strategic collaborations with Sanofi Genzyme, the specialty care global business unit of Sanofi, AbbVie, and the University of Massachusetts Medical School. Founded by scientific and clinical leaders in the fields of AAV gene therapy, expressed RNA interference and neuroscience, Voyager Therapeutics is headquartered in Cambridge, Massachusetts. For more information, please visit www.voyagertherapeutics.com.
Investor Relations:
Matt Osborne
Vice President, Investor Relations & Corporate Communications
857-259-5353
mosborne@vygr.com
Media:
Julie NormartW2O Group
+1 (415) 946-1087
jnormart@w2ogroup.com
Voyager Therapeutics, Inc.
